MELBOURNE, Australia--(BUSINESS WIRE)--Starpharma (ASX:SPL)(OTCQX:SPHRY) today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel.
Help employers find you! Check out all the jobs and post your resume.
